Real‐World nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma
Cancer Medicine · 2023-02 · 12 (3) · 2378-2388
DOI: 10.1002/cam4.5061 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Cancer Medicine, online erschienen am 25.07.2022. Verfasst von Wolfram Samlowski und 8 weiteren Autor:innen. Beteiligte Einrichtung: Comprehensive Cancer Centers of Nevada and University of Nevada Las Vegas Kirkorian School of Medicine, Las Vegas, Nevada, USA. Hauptthemen laut MEDLINE: Nivolumab, Melanoma. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bristol-Myers Squibb.
Abstract (Originalsprache)
Background
Nivolumab at a dose of 480 mg every 4 weeks (Q4W) is approved for the adjuvant treatment of melanoma. However, real‐world data on this regimen are limited in this setting.
Methods
This retrospective observational study utilized data from the US Oncology Network iKnowMed electronic health record database and patient medical charts. Eligible patients were diagnosed with melanoma and received adjuvant nivolumab monotherapy from March to August 2018. Patients were grouped by dosing regimen: cohort 1 (C1), de novo nivolumab 480 mg Q4W; cohort 2 (C2), switched to nivolumab 480 mg Q4W after nivolumab 240 mg or 3 mg/kg every 2 weeks (Q2W); cohort 3 (C3), de novo nivolumab 3 mg/kg Q2W; or cohort 4 (C4), de novo nivolumab 240 mg Q2W. Patients were followed for up to 12 months. Duration of therapy and safety/tolerability were assessed.
Results
One hundred ninety‐one patients were included (C1, n = 40; C2, n = 74; C3, n = 22; C4, n = 55). Duration of therapy was relatively consistent across cohorts (median, 10.3 months; range, 8.3–10.7). Likewise, proportions of patients experiencing treatment‐related adverse events (TRAEs) were similar (range, 54.5%–60.1%), as were the most common events (fatigue, rash, diarrhea, hypothyroidism, nausea, and pruritus). However, proportions experiencing ‘significant’ TRAEs varied between cohorts. Proportions discontinuing treatment were relatively consistent across cohorts. Propensity score matching and sensitivity analyses generally supported the unadjusted findings.
Conclusions
Real‐world safety profiles of nivolumab 240 mg Q2W and 480 mg Q4W were similar, and both were comparable to the well‐documented safety of weight‐based dosing (3 mg/kg Q2W), further supporting their approval and use in the adjuvant setting for melanoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Comprehensive Cancer Centers of Nevada and University of Nevada Las Vegas Kirkorian School of Medicine, Las Vegas, Nevada, USA.
- University of Nevada School of Medicine, Reno, Nevada, USA.
- McKesson Life Sciences, The Woodlands, Texas, USA.
- Bristol Myers Squibb, Princeton, New Jersey, USA.
- Perlmutter Cancer Center, NYU School of Medicine, New York, New York, USA.
ORCID-Profile: Wolfram Samlowski
Förderung
- Bristol-Myers Squibb
Zitieren
APA
Samlowski, W., Robert, N. J., Chen, L., Schenkel, B., Davis, C., Moshyk, A., Kotapati, S., Poretta, T., & Weber, J. S. (2023). Real‐World nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma. Cancer Medicine, 12(3), 2378-2388. https://doi.org/10.1002/cam4.5061
Vancouver
Samlowski W, Robert NJ, Chen L, Schenkel B, Davis C, Moshyk A, et al. Real‐World nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma. Cancer Medicine. 2023;12(3):2378-2388. doi:10.1002/cam4.5061
BibTeX
@article{Samlowski2023,
author = {Samlowski, Wolfram and Robert, Nicholas J and Chen, Liwei and Schenkel, Brad and Davis, Catherine and Moshyk, Andriy and Kotapati, Srividya and Poretta, Tayla and Weber, Jeffrey S},
title = {Real‐World nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma},
journal = {Cancer Medicine},
year = {2023},
volume = {12},
number = {3},
pages = {2378--2388},
doi = {10.1002/cam4.5061}
}
EUVIMED